Michael Naso, Janssen R&D to Present at GTCbio’s Cell & Gene Therapy Conference
Michael Naso, Janssen R&D will discuss, “The Future of Biotherapeutics” at GTCbio’s 3rd Cell & Gene Therapy
Boston, MA, June 30, 2016 --(PR.com)-- Michael Naso, Scientific Director at Janssen R&D, will give a presentation on “The Future of Biotherapeutics” at GTCbio’s 3rd Cell & Gene Therapy Conference to be held on September 12-13, 2016 in Boston, MA.
We are rapidly progressing our basic understanding of molecules and pathways that drive health and disease. The logical outcome of these efforts will be the identification of therapeutic intervention strategies that are specific for those pathways that are at the heart of the disease state. As target identification and validation efforts progress, we will be challenged by the current limitations of our therapeutic drug platforms. Small molecule drugs and biologics (large molecules) each have several significant issues with regard to the type of molecules they can effectively modulate, as well as, the costs associated their discovery and development. Gene therapies have the potential to accommodate all of these limitations, and could eventually replace current small molecule and biologics as the therapeutic platform of choice.
Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues and gain fresh perspective on the various research.
This conference is also part of their larger Modern Drug Discovery & Development Summit, which consists of three additional co-located conferences:
3rd Cell & Gene Therapy
11th Drug Design & Medicinal Chemistry
7th Non-Coding RNA & RNAi Therapeutics
4th GPCR in Drug Discovery
For more information, please visit website: www.gtcbio.com/cellandgenetherapy
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433
We are rapidly progressing our basic understanding of molecules and pathways that drive health and disease. The logical outcome of these efforts will be the identification of therapeutic intervention strategies that are specific for those pathways that are at the heart of the disease state. As target identification and validation efforts progress, we will be challenged by the current limitations of our therapeutic drug platforms. Small molecule drugs and biologics (large molecules) each have several significant issues with regard to the type of molecules they can effectively modulate, as well as, the costs associated their discovery and development. Gene therapies have the potential to accommodate all of these limitations, and could eventually replace current small molecule and biologics as the therapeutic platform of choice.
Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues and gain fresh perspective on the various research.
This conference is also part of their larger Modern Drug Discovery & Development Summit, which consists of three additional co-located conferences:
3rd Cell & Gene Therapy
11th Drug Design & Medicinal Chemistry
7th Non-Coding RNA & RNAi Therapeutics
4th GPCR in Drug Discovery
For more information, please visit website: www.gtcbio.com/cellandgenetherapy
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433
Contact
GTCbio
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
Fax: 626-466-4433
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
Fax: 626-466-4433
Contact
Categories